CIK 0001830487 · Large accelerated filer
Pharvaris N.V.
Sign in to watch- Ticker
- PHVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- other
- Phone
- 31 (0)71 203 6410
- Business address
- J.H. OORTWEG 21, 2333 CH LEIDEN, LEIDEN, Netherlands
- Former names
- Pharvaris, B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,335,217
- in 16 filings, $4.1M under 10b5-1 plans
Net −$20,335,217. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Schikan Johannes Gerardus Christiaan Petrus −$7.0M Director sold 64% of stake
- Lu Peng −$4.7M President sold 67% of stake
- Bjork Elisabeth −$2.0M Director sold 78% of stake
- Lesage Anne −$1.9M Chief Early Development sold 40% of stake
- Abele Stefan Andreas −$1.8M Chief Technical Ops Officer sold 54% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-22 | Nijdam Anna Principal Accounting Officer | Sale | −5,501 | $30.74 | $169K | 48,945 |
| 2026-05-22 | Nijdam Anna Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) | −5,501 | 22,670 | ||
| 2026-05-21 | Monges Viviane Director | Sale | −9,667 | $30.29 | $293K | 5,500 |
| 2026-05-21 | Nijdam Anna Principal Accounting Officer | Option exercise | +1,829 | $20.00 | $37K | 50,774 |
| 2026-05-21 | Nijdam Anna Principal Accounting Officer | Sale | −1,829 | $30.60 | $56K | 48,945 |
| 2026-05-21 | Nijdam Anna Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) | −1,829 | 28,171 | ||
| 2026-05-21 | Nassif David W. CFO / CLO | Sale | −10,000 | $30.31 | $303K | 120,300 |
| 2026-05-20 | Bjork Elisabeth Director | Option exercise 10b5-1 | +10,000 | $8.05 | $81K | 25,167 |
| 2026-05-20 | Bjork Elisabeth Director | Sale 10b5-1 | −10,000 | $29.32 | $293K | 15,167 |
| 2026-05-20 | Bjork Elisabeth Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 11,000 | ||
| 2026-05-18 | Modig Berndt Chief Executive Officer | Sale 10b5-1 | −2,292 | $29.22 | $67K | 137,500 |
| 2026-05-15 | Glassman Robert Director | Option exercise | +5,333 | $22.31 | $119K | 20,500 |
| 2026-05-15 | Glassman Robert Director | Sale | −5,333 | $29.83 | $159K | 15,167 |
| 2026-05-15 | Glassman Robert Director | Sale | −4,667 | $29.82 | $139K | 10,500 |
| 2026-05-15 | Glassman Robert Director | Option exercise · Stock Option (Right to Buy) | −5,333 | 8,667 | ||
| 2026-05-15 | Abele Stefan Andreas Chief Technical Ops Officer | Sale | −8,748 | $29.82 | $261K | 35,194 |
| 2026-05-15 | Souverijns Wim Chief Commercial Officer | Sale 10b5-1 | −10,000 | $29.92 | $299K | 45,111 |
| 2026-05-12 | Lu Peng Chief Medical Officer | Shares withheld for taxes | −117 | $29.95 | $4K | 65,857 |
| 2026-05-11 | Lu Peng Chief Medical Officer | Shares withheld for taxes | −109 | $30.09 | $3K | 65,974 |
| 2026-05-01 | Lu Peng Chief Medical Officer | Option exercise 10b5-1 | +14,166 | $2.59 | $37K | 80,249 |
Page 6 of 9 · 170 trades